keyword
https://read.qxmd.com/read/38635551/enhanced-cytotoxic-activity-of-natural-killer-cells-from-increased-calcium-influx-induced-by-electrical-stimulation
#1
JOURNAL ARTICLE
Minseon Lee, Soonjo Kwon
Natural killer (NK) cells play a crucial role in immunosurveillance independent of antigen presentation, which is regulated by signal balance via activating and inhibitory receptors. The anti-tumor activity of NK cells is largely dependent on signaling from target recognition to cytolytic degranulation; however, the underlying mechanism remains unclear, and NK cell cytotoxicity is readily impaired by tumor cells. Understanding the activation mechanism is necessary to overcome the immune evasion mechanism, which remains an obstacle in immunotherapy...
2024: PloS One
https://read.qxmd.com/read/38634521/cell-membrane-coated-nanoparticles-as-a-biomimetic-drug-delivery-platform-for-enhancing-cancer-immunotherapy
#2
REVIEW
Zichen Zhong, Wen Deng, Jian Wu, Haojie Shang, Yonghua Tong, Yu He, Qiu Huang, Xiaozhuo Ba, Zhiqiang Chen, Kun Tang
Cancer immunotherapy, a burgeoning modality for cancer treatment, operates by activating the autoimmune system to impede the growth of malignant cells. Although numerous immunotherapy strategies have been employed in clinical cancer therapy, the resistance of cancer cells to immunotherapeutic medications and other apprehensions impede the attainment of sustained advantages for most patients. Recent advancements in nanotechnology for drug delivery hold promise in augmenting the efficacy of immunotherapy. However, the efficacy is currently constrained by the inadequate specificity of delivery, low rate of response, and the intricate immunosuppressive tumor microenvironment...
April 18, 2024: Nanoscale
https://read.qxmd.com/read/38634218/the-noncanonical-nf%C3%AE%C2%BAb-pathway-regulatory-mechanisms-in-health-and-disease
#3
REVIEW
Benancio N Rodriguez, Helen Huang, Jennifer J Chia, Alexander Hoffmann
The noncanonical NFκB signaling pathway mediates the biological functions of diverse cell survival, growth, maturation, and differentiation factors that are important for the development and maintenance of hematopoietic cells and immune organs. Its dysregulation is associated with a number of immune pathologies and malignancies. Originally described as the signaling pathway that controls the NFκB family member RelB, we now know that noncanonical signaling also controls NFκB RelA and cRel. Here, we aim to clarify our understanding of the molecular network that mediates noncanonical NFκB signaling and review the human diseases that result from a deficient or hyper-active noncanonical NFκB pathway...
April 18, 2024: WIREs Mech Dis
https://read.qxmd.com/read/38634039/identification-and-validation-of-novel-metastasis-related-immune-gene-signature-in-breast-cancer
#4
JOURNAL ARTICLE
Shen Ma, Ran Hao, Yi-Wei Lu, Hui-Po Wang, Jie Hu, Yi-Xin Qi
BACKGROUND: Distant metastasis remains the leading cause of death among patients with breast cancer (BRCA). The process of cancer metastasis involves multiple mechanisms, including compromised immune system. However, not all genes involved in immune function have been comprehensively identified. METHODS: Firstly 1623 BRCA samples, including transcriptome sequencing and clinical information, were acquired from Gene Expression Omnibus (GSE102818, GSE45255, GSE86166) and The Cancer Genome Atlas-BRCA (TCGA-BRCA) dataset...
2024: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/38633930/sunscreen-safety-and-efficacy-for-the-prevention-of-cutaneous-neoplasm
#5
REVIEW
Jonathan R Raymond-Lezman, Suzanne I Riskin
Sunscreen is widely used for ultraviolet radiation protection. Studies validate sun protection factors (SPFs) to prevent ultraviolet (UV)-induced skin changes such as melanoma and squamous cell carcinoma (SCC). Few studies examine sunscreen's impact on endocrine and immune system dysregulation, the production of radical oxygen species, and whether the ingredients deteriorate under prolonged exposure. We present an investigation of sunscreen labels and how ingredients impact sun safety and human health. A review of the literature was conducted using Embase and PubMed to examine sunscreen safety, efficacy, and use to prevent UV-induced skin damage...
March 2024: Curēus
https://read.qxmd.com/read/38633673/pembrolizumab-with-bevacizumab-and-cyclophosphamide-for-the-treatment-of-recurrent-ovarian-clear-cell-carcinoma-a-case-series
#6
Shannon M Glynn, Stephanie Gaillard, Rebecca L Stone, Amanda N Fader, Anna L Beavis
INTRODUCTION: Treatment for recurrent ovarian clear cell carcinoma (OCCC) is clinically challenging as response rates to traditional chemotherapy are low, and recurrence rates are high. Immunotherapy has shown promise for this ovarian cancer (OC) subtype, and tumor molecular testing allows for the identification of a patient population that might benefit most from this treatment. We describe the clinical course and somatic genomic testing of 4 patients who received pembrolizumab for recurrent OCCC concurrent with a combination of bevacizumab and/or cyclophosphamide...
June 2024: Gynecologic Oncology Reports
https://read.qxmd.com/read/38633537/prognosis-of-immune-checkpoint-inhibitor-induced-myasthenia-gravis-a-single-center-experience-and-systematic-review
#7
Yuhui Qin, Siyuan Chen, Qian Gui, Teng Zhang, Yanan Li, Zhijuan Du, Yahui Lv, Xiangyu Du, Yi Hu, Zhefeng Liu
BACKGROUND: Immune checkpoint inhibitors (ICI)-induced myasthenia gravis (MG) is an uncommon but potentially fatal neurotoxicity. We aim to help physicians familiarize themselves with the clinical characteristics of ICI-induced MG, facilitating early diagnosis and prompt intervention. METHODS: We searched the Chinese People's Liberation Army General Hospital medical record system from January 2017 to August 2023 for patients diagnosed with ICI-induced MG. We systematically reviewed the literature until August 2023 to identify all similar patients...
2024: Frontiers in Neurology
https://read.qxmd.com/read/38633261/improve-a-feature-model-to-predict-neoepitope-immunogenicity-through-broad-scale-validation-of-t-cell-recognition
#8
JOURNAL ARTICLE
Annie Borch, Ibel Carri, Birkir Reynisson, Heli M Garcia Alvarez, Kamilla K Munk, Alessandro Montemurro, Nikolaj Pagh Kristensen, Siri A Tvingsholm, Jeppe Sejerø Holm, Christina Heeke, Keith Henry Moss, Ulla Kring Hansen, Anna-Lisa Schaap-Johansen, Frederik Otzen Bagger, Vinicius Araujo Barbosa de Lima, Kristoffer S Rohrberg, Samuel A Funt, Marco Donia, Inge Marie Svane, Ulrik Lassen, Carolina Barra, Morten Nielsen, Sine Reker Hadrup
BACKGROUND: Mutation-derived neoantigens are critical targets for tumor rejection in cancer immunotherapy, and better tools for neoepitope identification and prediction are needed to improve neoepitope targeting strategies. Computational tools have enabled the identification of patient-specific neoantigen candidates from sequencing data, but limited data availability has hindered their capacity to predict which of the many neoepitopes will most likely give rise to T cell recognition. METHOD: To address this, we make use of experimentally validated T cell recognition towards 17,500 neoepitope candidates, with 467 being T cell recognized, across 70 cancer patients undergoing immunotherapy...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38633256/detecting-t-cell-clonal-expansions-and-quantifying-clone-survival-using-deep-profiling-of-immune-repertoires
#9
JOURNAL ARTICLE
Anastasia V Pavlova, Ivan V Zvyagin, Mikhail Shugay
An individual's T-cell repertoire constantly changes under the influence of external and internal factors. Cells that do not receive a stimulatory signal die, while those that encounter and recognize a pathogen or receive a co-stimulatory signal divide, resulting in clonal expansions. T-cell clones can be traced by monitoring the presence of their unique T-cell receptor (TCR) sequence, which is assembled de novo through a process known as V(D)J rearrangement. Tracking T cells can provide valuable insights into the survival of cells after hematopoietic stem cell transplantation (HSCT) or cancer treatment response and can indicate the induction of protective immunity by vaccination...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38633247/coupled-scrna-seq-and-bulk-seq-reveal-the-role-of-hmmr-in-hepatocellular-carcinoma
#10
JOURNAL ARTICLE
Zhixiong Su, Yufang He, Lijie You, Guifeng Zhang, Jingbo Chen, Zhenhua Liu
BACKGROUND: Hyaluronan-mediated motility receptor (HMMR) is overexpressed in multiple carcinomas and influences the development and treatment of several cancers. However, its role in hepatocellular carcinoma (HCC) remains unclear. METHODS: The "limma" and "GSVA" packages in R were used to perform differential expression analysis and to assess the activity of signalling pathways, respectively. InferCNV was used to infer copy number variation (CNV) for each hepatocyte and "CellChat" was used to analyse intercellular communication networks...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38633245/whole-genome-sequencing-of-recombinant-viruses-obtained-from-co-infection-and-superinfection-of-vero-cells-with-modified-vaccinia-virus-ankara-vectored-influenza-vaccine-and-a-naturally-occurring-cowpox-virus
#11
JOURNAL ARTICLE
Diana Diaz-Cánova, Ugo Moens, Annika Brinkmann, Andreas Nitsche, Malachy Ifeanyi Okeke
Modified vaccinia virus Ankara (MVA) has been widely tested in clinical trials as recombinant vector vaccine against infectious diseases and cancers in humans and animals. However, one biosafety concern about the use of MVA vectored vaccine is the potential for MVA to recombine with naturally occurring orthopoxviruses in cells and hosts in which it multiplies poorly and, therefore, producing viruses with mosaic genomes with altered genetic and phenotypic properties. We previously conducted co-infection and superinfection experiments with MVA vectored influenza vaccine (MVA-HANP) and a feline Cowpox virus (CPXV-No-F1) in Vero cells (that were semi-permissive to MVA infection) and showed that recombination occurred in both co-infected and superinfected cells...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38632500/tissue-specific-atlas-of-trans-models-for-gene-regulation-elucidates-complex-regulation-patterns
#12
JOURNAL ARTICLE
Robert Dagostino, Assaf Gottlieb
BACKGROUND: Deciphering gene regulation is essential for understanding the underlying mechanisms of healthy and disease states. While the regulatory networks formed by transcription factors (TFs) and their target genes has been mostly studied with relation to cis effects such as in TF binding sites, we focused on trans effects of TFs on the expression of their transcribed genes and their potential mechanisms. RESULTS: We provide a comprehensive tissue-specific atlas, spanning 49 tissues of TF variations affecting gene expression through computational models considering two potential mechanisms, including combinatorial regulation by the expression of the TFs, and by genetic variants within the TF...
April 17, 2024: BMC Genomics
https://read.qxmd.com/read/38631714/efficacy-of-lcmv-based-cancer-immunotherapies-is-unleashed-by-intratumoral-injections-of-polyi-c
#13
JOURNAL ARTICLE
Celia Gomar, Claudia Augusta Di Trani, Angela Bella, Leire Arrizabalaga, Jose Gonzalez-Gomariz, Myriam Fernandez-Sendin, Maite Alvarez, Joan Salvador Russo-Cabrera, Nuria Ardaiz, Fernando Aranda, Timo Schippers, Marisol Quintero, Ignacio Melero, Klaus K Orlinger, Henning Lauterbach, Pedro Berraondo
BACKGROUND: Lymphocytic choriomeningitis virus (LCMV) belongs to the Arenavirus family known for inducing strong cytotoxic T-cell responses in both mice and humans. LCMV has been engineered for the development of cancer immunotherapies, currently undergoing evaluation in phase I/II clinical trials. Initial findings have demonstrated safety and an exceptional ability to activate and expand tumor-specific T lymphocytes. Combination strategies to maximize the antitumor effectiveness of LCMV-based immunotherapies are being explored...
April 16, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38631709/preclinical-evaluation-of-two-phylogenetically-distant-arenavirus-vectors-for-the-development-of-novel-immunotherapeutic-combination-strategies-for-cancer-treatment
#14
JOURNAL ARTICLE
Josipa Raguz, Catarina Pinto, Theresa Pölzlbauer, Mohamed Habbeddine, Sandra Rosskopf, Judith Strauß, Valentin Just, Sarah Schmidt, Katell Bidet Huang, Felix Stemeseder, Timo Schippers, Ethan Stewart, Jakub Jez, Pedro Berraondo, Klaus K Orlinger, Henning Lauterbach
BACKGROUND: Engineered arenavirus vectors have recently been developed to leverage the body's immune system in the fight against chronic viral infections and cancer. Vectors based on Pichinde virus (artPICV) and lymphocytic choriomeningitis virus (artLCMV) encoding a non-oncogenic fusion protein of human papillomavirus (HPV)16 E6 and E7 are currently being tested in patients with HPV16+ cancer, showing a favorable safety and tolerability profile and unprecedented expansion of tumor-specific CD8+ T cells...
April 17, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38631708/preclinical-evaluation-and-first-in-dog-clinical-trials-of-pbmc-expanded-natural-killer-cells-for-adoptive-immunotherapy-in-dogs-with-cancer
#15
JOURNAL ARTICLE
Aryana M Razmara, Lauren E Farley, Rayna M Harris, Sean J Judge, Marshall Lammers, Khurshid R Iranpur, Eric G Johnson, Cordelia Dunai, William J Murphy, C Titus Brown, Robert B Rebhun, Michael S Kent, Robert J Canter
BACKGROUND: Natural killer (NK) cells are cytotoxic cells capable of recognizing heterogeneous cancer targets without prior sensitization, making them promising prospects for use in cellular immunotherapy. Companion dogs develop spontaneous cancers in the context of an intact immune system, representing a valid cancer immunotherapy model. Previously, CD5 depletion of peripheral blood mononuclear cells (PBMCs) was used in dogs to isolate a CD5dim -expressing NK subset prior to co-culture with an irradiated feeder line, but this can limit the yield of the final NK product...
April 16, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38631695/the-early-stage-clinical-course-of-anti-pituitary-specific-transcription-factor-1-hypophysitis-diagnosed-post-immune-checkpoint-inhibitor-treatment-a-case-with-review-of-literature
#16
JOURNAL ARTICLE
Shin Urai, Seiji Tomofuji, Hironori Bando, Maki Kanzawa, Masaaki Yamamoto, Hidenori Fukuoka, Masahiro Tsuda, Genzo Iguchi, Wataru Ogawa
Anti-pituitary-specific transcription factor-1 (PIT-1) hypophysitis, a paraneoplastic syndrome resulting from an autoimmune response against PIT-1, typically manifests with undetectable levels of growth hormone (GH) and prolactin (PRL), and significantly low levels of serum thyroid-stimulating hormone (TSH) at diagnosis. These hormonal levels are highly specific to this disease and serve as key diagnostic indicators. Herein, we present a detailed clinical course of a 69-year-old male with a history of gastric cancer and lymph node metastases who developed anti-PIT-1 hypophysitis after the initiation of immune checkpoint inhibitor (ICI) therapy, specifically nivolumab, oxaliplatin, and capecitabine...
April 17, 2024: Journal of Neuroendocrinology
https://read.qxmd.com/read/38631104/real-world-analysis-of-peritoneal-metastasis-from-renal-cell-carcinoma-meet-uro27
#17
JOURNAL ARTICLE
Marco Stellato, Sebastiano Buti, Marco Maruzzo, Maria Bassanelli, Melissa Bersanelli, Marilena Di Napoli, Michele Dionese, Martina Fanelli, Roberto Filippi, Giuseppe Fotia, Luca Galli, Francesco Grillone, Michele Maffezzoli, Brigida Anna Maiorano, Cecilia Nasso, Sara Elena Rebuzzi, Luca Lalli, Giandomenico Roviello, Mariella Sorarù, Bruno Vincenzi, Giuseppe Procopio, Elena Verzoni
BACKGROUND: Peritoneal metastases (PM) have been reported in approximately 1% of patients with metastatic Renal Cell Carcinoma (mRCC). Outcome data are limited due to the rarity of this metastatic site. Therefore, the aim of our study is to describe renal cell carcinoma (RCC) patients with PM treated as per clinical practice. MATERIALS AND METHODS: Baseline characteristics and outcome data of patients with PM from RCC were retrospectively collected from 18 Italian oncological referral centers adhering to the Meet-Uro group, from January 2016 to January 2023...
March 19, 2024: Clinical Genitourinary Cancer
https://read.qxmd.com/read/38631025/melanoma-clonal-heterogeneity-leads-to-secondary-resistance-after-adoptive-cell-therapy-with-tumor-infiltrating-lymphocytes
#18
JOURNAL ARTICLE
David König, Michael Sandholzer, Sarp Uzun, Andreas Zingg, Reto Ritschard, Helen Thut, Katharina Glatz, Elisabeth A Kappos, Dirk J Schaefer, Christoph Kettelhack, Jakob R Passweg, Andreas Holbro, Katharina Baur, Michael Medinger, Andreas Buser, Didier Lardinois, Lukas T Jeker, Nina Khanna, Frank Stenner, Benjamin Kasenda, Krisztian Homicsko, Matthias Matter, Natalia Rodrigues Mantuano, Alfred Zippelius, Heinz Läubli
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is effective in melanoma patients, although long-term responses seem restricted to patients who have complete remissions. Many patients develop secondary resistance to TIL-ACT but the involved mechanisms are unclear. Here, we describe a case of secondary resistance to TIL-ACT likely due to intratumoral heterogeneity and selection of a resistant tumor cell clone by the transferred T cells. To our knowledge, this is the first case of clonal selection of a pre-existing non-dominant tumor cell clone and it demonstrates a mechanism involved in secondary resistance to TIL-ACT that could potentially change current clinical practice, because it advocates for T-cell collection from multiple tumor sites and analysis of tumor heterogeneity before the treatment with TIL-ACT...
April 17, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38631019/orchestrated-codelivery-of-peptide-antigen-and-adjuvant-to-antigen-presenting-cells-by-using-an-engineered-chimeric-peptide-enhances-antitumor-t-cell-immunity
#19
JOURNAL ARTICLE
Haifeng Pan, Siyuan Yu, Haoyun Zhuang, Han Yang, Jinlu Jiang, Haihui Yang, Shuling Ren, Guoxing Luo, Xuan Yu, Shuping Chen, Yanhua Lin, Roufang Sheng, Shiyin Zhang, Quan Yuan, Chenghao Huang, Tianying Zhang, Tingdong Li, Shengxiang Ge, Jun Zhang, Ningshao Xia
The intrinsic pharmacokinetic limitations of traditional peptide-based cancer vaccines hamper effective cross-presentation and codelivery of antigens and adjuvants, which are crucial for inducing robust antitumor CD8+ T-cell responses. Here, we report the development of a versatile strategy that simultaneously addresses the different pharmacokinetic challenges of soluble subunit vaccines composed of antigens and CpG to modulate vaccine efficacy via translating an engineered chimeric peptide, eTAT, as an intramolecular adjuvant...
April 17, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38630912/preclinical-models-for-bladder-cancer-therapy-research
#20
JOURNAL ARTICLE
Iris Ertl, Shahrokh F Shariat, Walter Berger, Bernard Englinger
PURPOSE OF REVIEW: Bladder cancer (BC) is a highly heterogenous disease comprising tumours of various molecular subtypes and histologic variants. This heterogeneity represents a major challenge for the development of novel therapeutics. Preclinical models that closely mimic in vivo tumours and reflect their diverse biology are indispensable for the identification of therapies with specific activity in various BC subtypes. In this review, we summarize efforts and progress made in this context during the last 24 months...
April 17, 2024: Current Opinion in Urology
keyword
keyword
165708
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.